Imaging features of haematological malignancies of kidneys.
Sandrasegaran K et al. Clin Radiol. 2015 Dec 11. pii: S0009-9260(15)00444-4. doi: 10.1016/j.crad.2015.11.007. [Epub ahead of print].

Minimal tumour burden in haematological diseases: a step forward with quantitative assessment of Bence-Jones in nephelometry?
Pieri M et al. Br J Haematol. 2015 Dec 18. doi: 10.1111/bjh.13878. [Epub ahead of print].

ANNALS EXPRESS: Low IgA levels detected via the tissue transglutaminase assay can reveal previously undetected monoclonal proteins.
Wallage M et al. Ann Clin Biochem. 2015 Dec 17. pii: 0004563215625692. [Epub ahead of print].

The potential diagnostic power of extracellular vesicle analysis for multiple myeloma.
Canella A et al. Expert Rev Mol Diagn. 2015 Dec 15. [Epub ahead of print].

Gene signature combinations improve prognostic stratification of multiple myeloma patients.
Chng WJ et al. Leukemia. 2015 Dec 16. doi: 10.1038/leu.2015.341. [Epub ahead of print].

Utility of haematology analyzer and flow cytometry in timely and correct detection of circulating plasma cells: Report of three cases.
Gounari E et al. Cytometry B Clin Cytom. 2015 Dec 10. doi: 10.1002/cyto.b.21350. [Epub ahead of print].

Suppression of the non-involved pair of the myeloma isotype (HLC-matched pair) correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma.
Ludwig H et al. Am J Hematol. 2015 Dec 10. doi: 10.1002/ajh.24268. [Epub ahead of print].

Whole body diffusion weighted MRI: A new gold standard for assessing disease burden in patients with multiple myeloma?
Pawlyn C et al. Leukemia. 2015 Dec 9. doi: 10.1038/leu.2015.338. [Epub ahead of print].

FOXM1 is a therapeutic target for high-risk multiple myeloma.
Gu C et al. Leukemia. 2015 Dec 9. doi: 10.1038/leu.2015.334. [Epub ahead of print].

Is accuracy of serum free light chain measurement achievable?
Jacobs JF et al. Clin Chem Lab Med. 2015 Dec 7. pii: /j/cclm.ahead-of-print/cclm-2015-0879/cclm-2015-0879.xml. doi: 10.1515/cclm-2015-0879. [Epub ahead of print].

Use of isoelectric focusing to discriminate transient oligoclonal bands from monoclonal protein in treatedmyeloma.
Henry R et al. Clin Chem Lab Med. 2015 Dec 7. pii: /j/cclm.ahead-of-print/cclm-2015-0642/cclm-2015-0642.xml. doi: 10.1515/cclm-2015-0642. [Epub ahead of print].

Lower expression of activating transcription factors 3 and 4 correlates with shorter progression-free survival inmultiple myeloma patients receiving bortezomib plus dexamethasone therapy.
Narita T et al. Blood Cancer J. 2015 Dec 4;5:e373. doi: 10.1038/bcj.2015.98.

Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma.
Dejoie T et al. Haematologica. 2015 Dec 3. pii: haematol.2015.126797. [Epub ahead of print].

Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival inmultiple myeloma.
Wang L et al. Oncotarget. 2015 Dec 1;6(38):41228-36. doi: 10.18632/oncotarget.5682.

Predictive Value of Glycated Hemoglobin and Body Mass Index for Pretreatment Neuropathy in Patients With Multiple Myeloma.
Lakshman A et al. Clin Lymphoma Myeloma Leuk. 2015 Nov 3. pii: S2152-2650(15)01337-3. doi: 10.1016/j.clml.2015.10.005. [Epub ahead of print].